Objective To appraise the availability, quality, and inclusivity of clinical guidelines produced in the early stage of the coronavirus disease 2019 (covid-19) pandemic. Design Rapid review. Data sources Ovid Medline, Ovid Embase, Ovid Global Health, Scopus, Web of Science Core Collection, and WHO Global Index Medicus, searched from inception to 14 Mar 2020. Search strategies applied the CADTH database guidelines search filter, with no limits applied to search results. Further studies were identified through searches of grey literature using the ISARIC network. Inclusion criteria Clinical guidelines for the management of covid-19, Middle East respiratory syndrome (MERS), and severe acute respiratory syndrome (SARS) produced by international and national scientific organisations and government and non-governmental organisations relating to global health were included, with no exclusions for language. Regional/hospital guidelines were excluded. Only the earliest version of any guideline was included. Quality assessment Quality was assessed using the Appraisal of Guidelines for Research and Evaluation (AGREE) II tool. The quality and contents of early covid-19 guidelines were also compared with recent clinical guidelines for MERS and SARS. Results 2836 studies were identified, of which 2794 were excluded after screening. Forty two guidelines were considered eligible for inclusion, with 18 being specific to covid-19. Overall, the clinical guidelines lacked detail and covered a narrow range of topics. Recommendations varied in relation to, for example, the use of antiviral drugs. The overall quality was poor, particularly in the domains of stakeholder involvement, applicability, and editorial independence. Links between evidence and recommendations were limited. Minimal provision was made for vulnerable groups such as pregnant women, children, and older people. Conclusions Guidelines available early in the covid-19 pandemic had methodological weaknesses and neglected vulnerable groups such as older people. A framework for development of clinical guidelines during public health emergencies is needed to ensure rigorous methods and the inclusion of vulnerable populations. Systematic review registration PROSPERO CRD42020167361.

中文翻译：

---

covid-19 大流行早期制定的临床指南的范围、质量和包容性：快速审查。

目的 评估 2019 年冠状病毒病 (covid-19) 大流行早期阶段制定的临床指南的可用性、质量和包容性。设计快速审查。数据来源 Ovid Medline、Ovid Embase、Ovid Global Health、Scopus、Web of Science Core Collection 和 WHO Global Index Medicus，检索时间从开始到 2020 年 3 月 14 日。检索策略应用 CADTH 数据库指南检索过滤器，对检索没有限制结果。通过使用 ISARIC 网络搜索灰色文献，确定了进一步的研究。纳入标准 纳入了由与全球健康相关的国际和国家科学组织以及政府和非政府组织制定的治疗 covid-19、中东呼吸综合征 (MERS) 和严重急性呼吸综合征 (SARS) 的临床指南，其中不排除语言。地区/医院指南被排除在外。仅包含任何指南的最早版本。质量评估 使用研究和评估指南评估 (AGREE) II 工具评估质量。早期的 covid-19 指南的质量和内容也与最近的 MERS 和 SARS 临床指南进行了比较。结果共识别出 2836 项研究，其中 2794 项经筛选后被排除。42 条指南被认为有资格纳入其中，其中 18 条专门针对 covid-19。总体而言，临床指南缺乏细节且涵盖的主题范围狭窄。例如，在使用抗病毒药物方面，建议各不相同。总体质量很差，特别是在利益相关者参与、适用性和编辑独立性方面。证据和建议之间的联系是有限的。为孕妇、儿童和老年人等弱势群体提供了最低限度的保障。结论 covid-19 大流行早期的指南存在方法上的缺陷，并且忽视了老年人等弱势群体。需要制定突发公共卫生事件期间临床指南的框架，以确保采用严格的方法并纳入弱势群体。系统审评注册PROSPERO CRD42020167361。